BLCO Stock Recent News

Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2024 Results Conference Call February 19, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations Brent Saunders - CEO & Chairman Sam Eldessouky - Executive VP & CFO Yehia Hashad - Head of R&D and Chief Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley Joanne Wuensch - Citibank Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Denis Reznik - Raymond James Operator Greetings. Welcome to the Bausch + Lomb Fourth Quarter 2024 Earnings Call.

While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed out.

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bausch + Lomb (BLCO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation.

Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

It was quite a busy and eventful day for the company.

Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company.

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors.